Femoston as a hormone replacement therapy for ovarian failure
- Authors: Repinа M.A.1, Zinina T.A.1, Korzo T.M.1
-
Affiliations:
- St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
- Issue: Vol 48, No 1 (1999)
- Pages: 94-100
- Section: Viewpoint
- URL: https://journals.rcsi.science/jowd/article/view/88690
- DOI: https://doi.org/10.17816/JOWD88690
- ID: 88690
Cite item
Full Text
Abstract
The article presents the results of a number of hemostasis parameters (coagulation, vascular and thrombocytic) and lipoprotein spectra, including apo A-1 and apo B100 apoproteins against the background of hormone replacement treatment with Femostone (Solvay, Germany). The results were compared taking into account menstrual cycle phases in perimenopausal patients (with a preserved cycle) and conditional estrogenic, progestagenic phases of Femostone administration. The advantages of the progestagen didrogesterone included in the drug in its effect on the lipid spectrum, apoproteins and some parameters of vascular thrombocyte hemostasis are shown.
Full Text
##article.viewOnOriginalSite##About the authors
M. A. Repinа
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: info@eco-vector.com
Russian Federation, St. Petersburg
T. A. Zinina
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: info@eco-vector.com
Russian Federation, St. Petersburg
T. M. Korzo
St. Petersburg Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: info@eco-vector.com
Russian Federation, St. Petersburg